Schizophrenia/Psychosis

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.

New research underlies the need for addressing identity in young patients during early stages of psychosis.

An explanation for the clinical presentation of delusions and hallucinations may have just been found.

More than 50% of patients with schizophrenia are estimated to be nonadherent with their antipsychotic medication regimen. What treatment solutions are available?

Antipsychotic medications for young children are not being prescribed appropriately, according to a recent study.

Data from a randomized phase III trial shows promise for new treatment strategy.

Researchers investigated in-hospital mortality and ICU admission in patients with COVID-19 with and without comorbid schizophrenia in a population-based cohort study.

A new, unique long-acting injectable for treating schizophrenia may be on the way.

When switching to this long-acting injectable antipsychotic, how long should an oral pre-switch antipsychotic be continued? Find out in this quiz.

This case illustrates the practical implications and effectiveness of the Minnesota Multiphasic Personality Inventory-2 in documenting patient recovery during treatment for delusional disorder.

Alkermes plc’s new drug, ALKS 3831, pending FDA approval, could be helpful in the treatment of patients with schizophrenia or bipolar I disorder.

Abnormal glutamate and GABA levels may underlie cognitive deficits. A recent study investigated these associations in a large group of antipsychotic-naïve patients with first-episode psychosis.

Schizophrenia is associated with an increased prevalence of alcohol use disorders. A post-hoc analysis of the clinical course of the 2 disorders is an important change in this understudied and often overlooked population.

Do neurological signs at illness onset predict long-term outcome schizophrenia?

The acute psychotomimetic effect of cannabis is transitory, but evidence indicates that the chronic use, especially if started in adolescence, contributes to the occurrence of schizophrenia.

Does cognition predict outcomes in patients at clinical high-risk for psychosis?

In comparison to the classic presentation of schizophrenia, ANMDARE features a later age of onset, female predominance, visual hallucinations, relative lack of cognitive disorganization, and a lack of an extended prodromal period.

The role of the oropharyngeal microbiome in schizophrenia and mania.

The biggest challenge we have faced thus far has been a three-fold rise in requests for assistance in managing persistent delirium. Needless to say, we are not twiddling our thumbs.

A nationwide cohort study sought to determine the clinical course of schizophrenia in women and men in order to improve diagnostic accuracy and design guidelines.

The role of neuroimaging is to rule out medically or surgically treatable causes of illness, such as new-onset psychosis.

When the patient has significant comorbid psychiatric problems, high risk of suicide, and Huntington disease, the role of clinician spills over into patient advocate in a complex medical system.

With adequate clinician awareness and prompt initiation of diagnostic testing and intervention, patients with autoimmune encephalitis can lead productive lives. A range of tests is described here.

Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.